A couple of links concerning the recently reported TRIUMPH trial, an utter failure in treating cardiogenic shock. Much different agent used; the crux of the post is to point to recent trial design/patient population for the same indication.
theheart.org
medpagetoday.com
If Cardiome is correct about Protein C being an accurate biomarker, good. Dr. Hochman, the TRIUMPH PI, didn't seem to be aware of it. Something to look at right there (it's a parameter in the APACHE system for Xigris & sepsis)? I gather the Protein C level is higher in cardiogenic shock as opposed to sepsis, but I could be all wet there. Can't find any freebies on that subject.
I understand about the literature hits versus knowledge gap thing. All I was going to do was see if Xigris had other safety issues than what has been discussed here, because I don't remember (if I ever knew). Then we can take whatever we find & ask someone with an actual scientific background if it's a concern. Tomorrow, perhaps I'll start.
I agree the near term driver is oral rsd 1235. It's just that I was looking for a re-entry, and this has presented a possible opportunity, but clouds the issue a bit, inasmuch as they will devoting resources to this project, and it's at least as risky as the others. I have not listened to the CC. I'll get round to it, but thanks for your notes.
Cheers, Tuck |
